Bright Future for Gene Therapy in Hematologic Malignancies – OncLive
OncLive |
Bright Future for Gene Therapy in Hematologic Malignancies
OncLive Chimeric antigen receptor (CAR) T-cell therapy has been named the Advance of the Year in the American Society of Clinical Oncology's (ASCO's) Clinical Cancer Advances 2018. 1 It's not hard to understand why. CAR T-cell therapy is unique among … |
